Could Anivive's FIP Drug Treat COVID-19? Drs. Dave Bruyette, Chad Dodd, and CEO Dylan Balsz

Published: June 3, 2020, 12:28 p.m.

b"Could an experimental Feline Infectious Peritonitis (FIP) drug be the secret to treating human COVID-19? \\n\\u2026\\nThis week we\\u2019re thrilled to bring you an exclusive interview with the California-based Anivive Lifesciences team to discuss their recent FDA submittal to use their experimental FIP drug on human coronavirus patients. \\n\\u2026\\nAnivive\\u2019s Founder & CEO, Mr. Dylan Balsz joins us along with Dr. David Bruyette, Chief Medical Officer, and Dr. Chad Dodd, Chief Commercial Officer to share their exciting story.\\n\\u2026\\nHosts Dr. Ernie Ward and Beckie Mossor, RVT learn about how a companion animal drug company\\u2019s deep research and experience with coronaviruses is helping develop an advanced treatment for humans suffering from COVID-19.\\n\\u2026\\nThis conversation emphasizes the importance of the One Health concept, how veterinarians are uniquely poised to tackle pandemics, and the exciting prospects for using software to accelerate biotechnologies and usher in medical breakthroughs for both humans and animals. \\n...\\nAnd Dr. Dave Bruyette. Anytime you have the chance to learn from Dr. Bruyette, don't pass it up! \\n\\u2026\\nFor more information, visit \\xa0https://www.anivive.com/"